IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

Outcomes after intensive ADT and surgery in high-risk men with localized disease

The initial results of a small Phase II trial of androgen deprivation therapy (ADT) + abiraterone acetate prior to surgery in high-risk patients have now been published. … READ MORE …

Use of bisphosphonate therapy in men on ADT in Ontario, Canada

According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …

Survival of prostate cancer patients diagnosed with M1 disease in the modern era

Back in the late 1980s and early 1990s, the projected survival time for a man diagnosed with evident metastatic prostate cancer (then called D2 disease and now known as TxNxM1 disease) was about 18 to 36 months. Has that really changed in the past 25 years? … READ MORE …

First 6 months of first off-therapy cycle may determine effectiveness of intermittent ADT

A new paper in Clinical Genitourinary Cancer provides some intriguing information about determining the likelihood of good and less good long-term responses to intermittent androgen deprivation therapy (ADT) among men with non-metastatic prostate cancer. Be warned: This is going to be a long post with a lot of data. … READ MORE …

Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,242 other followers